Medical Research Commercialisation Fund (MRCF) logo

Medical Research Commercialisation Fund (MRCF)

Oceania, Victoria, Australia, Melbourne

Description

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage

Investor Profile

Medical Research Commercialisation Fund (MRCF) has made 6 investments, with 0 in the past 12 months and 33% as lead.

Stage Focus

  • Series A (67%)
  • Series Unknown (33%)

Country Focus

  • United Kingdom (50%)
  • Australia (33%)
  • United States (17%)

Industry Focus

  • Biotechnology
  • Health Care
  • Biopharma
  • Therapeutics
  • Medical
  • Pharmaceutical
  • Life Science
  • Medical Device
  • Cosmetic Surgery
  • Landscaping
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Medical Research Commercialisation Fund (MRCF) frequently co-invest with?

Bupa
Europe, England, United Kingdom, London
Co-Investments: 1
Canaan Partners
North America, California, United States, Menlo Park
Co-Investments: 1
HealthCare Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Sante Ventures
North America, Texas, United States, Austin
Co-Investments: 1
Imperial Innovations
Europe, England, United Kingdom, London
Co-Investments: 1
OneVentures
Oceania, New South Wales, Australia, Sydney
Co-Investments: 2
AbbVie Biotech Ventures
North America, Illinois, United States, North Chicago
Co-Investments: 1
Brandon Capital
Oceania, Victoria, Australia, Melbourne
Co-Investments: 4

What are some of recent deals done by Medical Research Commercialisation Fund (MRCF)?

Glyscend Therapeutics

Baltimore, Maryland, United States

Glyscend develops a revolutionary approach to treating type 2 diabetes.

BiopharmaBiotechnologyCosmetic SurgeryLandscapingMedicalPharmaceuticalTherapeutics
Series AJun 11, 2020
Amount Raised: $19,803,671
George Medicines

London, England, United Kingdom

George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.

Health CareManufacturingPharmaceutical
Series UnknownMar 9, 2020
Amount Raised: $35,298,270
Pathios Therapeutics

Oxford, Oxfordshire, United Kingdom

Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.

BiotechnologyHealth CareTherapeutics
Series ADec 18, 2019
Amount Raised: $13,200,000
Paragen Bio

Brisbane, Queensland, Australia

Paragen Bio is a provider of a technology intended to treat autoimmune diseases.

BiopharmaBiotechnologyLife Science
Series UnknownAug 14, 2018
Amount Raised: $4,341,390
Auspherix

Stevenage, Herefordshire, United Kingdom

Auspherix is an Australian early stage anti-infectives company developing novel antibiotics to treat resistant bacterial diseases.

BiotechnologyHealth CareMedical
Series AJun 3, 2015
Amount Raised: $9,197,249
Vaxxas

Brisbane, Queensland, Australia

Vaxxass is a biotechnology company focused on needle-free vaccination technology.

BiotechnologyHealth CareMedical Device
Series AAug 2, 2011
Amount Raised: $16,237,228